Hydroxy-PP-Me

Cat. No.:	HY-156694		
CAS No.:	833481-77-9		
Molecular Formula:	$C_{16}H_{18}N_4O$		
Molecular Weight:	282.34		
Target:	Apoptosis		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (354.18 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.5418 mL	17.7091 mL	35.4183 mL
	5 mM	0.7084 mL	3.5418 mL	7.0837 mL
	10 mM	0.3542 mL	1.7709 mL	3.5418 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 2.5 mg/mL (8.85 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (8.85 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (8.85 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Hydroxy-PP-Me is a potent and specific CBR1 inhibitor with an IC_{50} of 759 nM. Hydroxy-PP-Me inhibits serum-withdrawal-induced apoptosis. Hydroxy-PP-Me increases As_2O_3-induced apoptotic cell death compared with As_2O_3 alone[1][2].

IC_{50} & Target

IC50: 759 nM (CBR1)[1]

REFERENCES

[1]. Tanaka M, et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005 May;3(5):e128.

[2]. Jang M, et al. Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res. 2012 Aug 15;72(16):4214-24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA